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Spironolactone and potassium canrenoate are diuretics widely 
used for management of cirrhotic ascites. The administration of 
spironolactone frequently leads to feminization, which has been 
noted less frequently with the use of potassium canrenoate, a 
salt of the active metabolite of spironolactone. The use of these 
two drugs has been associated with decreases in serum testos-
terone levels and in case of spironolactone with a reduction in 
androgen receptor (AR) activity (8,10,19,20,23,25-28). 
Considering the critical role of the liver in sex hormone me-
tabolism the study about the effects of these drugs on liver sex 
hormone receptor state, could add new informations for under-
standing the mechanism of feminization by these two drugs. We 
report here the effect of spironolactone and potassium canrenoate 
treatment on the sex hormone receptor and androgen responsive 
protein status of the liver and the effects of these treatments 
on serum estrogen and testosteron levels. 
MATERIALS AND METHODS 
Animals 
Three groups of adult male Sprague Dawley rats (240 gr b.w.) 
were studied. Animals in the control group (group 1) were 
I 
i' 
242 ANTIALDOSTERONIC DIURETICS AND RAT LIVER 
injected intraperitoneally with 0.5 ml of a solution of 
physiologic salin with TWEEN 80 (0.1% v/v). The rats in the other 
groups received 5 mg of spironolactone (group 2) or 5 mg of 
potassium canrenoate (group 3) dissolved in the same vehicle. All 
animals were injected daily for 21 days and killed by decapita-
tion after that time. 
Materials 
Estradiol (E2) and Dihydrotestosterone were purchased from 
Steraloids, Wilton, NH. Spironolactone and Potassium Canrenoate 
were from SPA, Milan, Italy. Diethylstilbestrol (DEB), Leupeptin, 
Benzamidine, Bovine serum Albumin, Sodium Molybdate, Protamine 
Sulfate and other buffer component were purchased from Sigma 
Chemical Co., St. Louis, MO. Norit A and Dextran C were obtained 
from Fisher Scientific Co., Pittsburgh, PA. Radioactive 
(2,4,6,7,16,17)- 3H -E2 (131 Ci/rnrnol), 17 -methyl- 3H -
methyltrienolone (3H -RI881) (79 Ci/rnrnol) and nonradioactive 
R1881 were obtained from New England Nuclear, Boston, MA. In-
stagel scintillation fluid was purchased from Packard Instrument 
Co., Downers Grove, IL. The radiolabeled steroids used in these 
studies were assayed periodically for purity by thin layer 
chromatography on silica gel G in ethyl acetate/hexane/ethanol 
(85:10:5), and were used only if purity was> 95%. 
Assay of nuclear and cytosolic Sex-Steroid receptors 
Nuclear and cytosolic Sex-Steroid receptors were evaluated by 
the method previously described by us (11,14,16-18). 
Assay of androgen-responsive male estrogen binding protein 
Assay for the determination of cytosolic content of a male 
specific estrogen binding protein (MEB) has been described pre-
viously (12,34). Briefly, cytosol is pre incubated for 1 h at 0 °c 
with· 500 nM DES to block the estrogen receptor. The cytosol is 
then incubated with 5 nM 3H-E2 in the absence and presence of 
5 M unlabeled E2 for 2 h a 0 °c. Bound and free steroids are 
separated by centrifuge-assisted BioGel P-6 chromatography (34). 
This assay is quantitative for MEB and is linear over a broad 
range of protein concentration. 
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Other methods 
Protein concentrations: method of Bradford (5). 
DNA concentrations of homogenates and nuclear preparations: 
method of Burton (6). 
Cytosolic 
the basis of 
receptor content for each animal was calculated on 
3H -steroid bound/mg cytosol protein, and then cor-
rected for yeld of cytosolic protein for gram of liver. Nuclear 
receptor content was calculated on the basis of 3H -steroid 
bound/mg DNA recovered in the nuclear preparation, and then cor-
rected for the DNA content of the original homogenate. For each 
animal, the total liver content of receptor represents the sum of 
the cytosolic and nuclear content based on 1 gram of liver. 
Cytosolic contamination of nuclei was assayed by determining the 
activity of alcohol dehydrogenase (37) in the homogenate, cytosol 
and the washed nuclei preparation and was found to be less than 
0.5% of that found in the nuclear preparation. The average 
recovery of DNA in the nuclear preparation was 72.8% of that in 
the homogenate. 
Serum testosterone, estradiol and other hormones were deter-
mined by specific radioimmunoassays as described previously (38). 
Equilibrium dissociation constants (Kd's) and the concentra-
tions of binding sites were calculated by the method of Scatchard 
(35) • 
Statistical analyses were performed using the Student's t-test 
program. 
Radioactivity content of samples was determined using a Pack-
ard TriCarb 5430 Liquid Scintillation System. 
RESULTS 
In spironolactone treated animals there is a significant 
decrease in testosterone levels; all other gonadal and pituitary 
hormone levels in this group are comparable to those of the con-
trol animals. In potassium canrenoate treated rats no change was 
observed in either testosterone or estradiol levels, although 
significant reductions in progesterone and DHEAS was found. 
Cytosolic AR levels (cAR) are significantly higher in K can-
renoate treated rats as compared with those observed in either 
control animals or spironolactone treated ones. There were no 
variations in the affinity of the cAR for its ligand in any 
groups studied. The Kd values for cAR were 0.26+0.06 nM, 
0.25+0.08 nM and 0.31+0.04 nM for group I, II and III respec-
tively (Tab I). 
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The activity of nuclear androgen receptor (nAR) , however, 
presents a markedly different picture, and is significantly 
decreased in the animals treated with either spironolactone or 
potassium canrenoate. 
As a result of these variations, the total AR content of the 
liver changed significantly only in those animals treated with 
spironolactone (50% decrease from normal levels). Interestingly, 
the activity of total androgen receptors in the spironolactone 
treated animals shows a decrease proportional to that of plasma 
testosterone. 
Tab I: Variation in specific 3H -R1881 in rat liver 
CONTROL 
SPIRO 
K-CAN 
3H -R1881 specific binding (fmol/g liver) 
TOTAL 
364+62 
170+38 
(P<0.05) 
347+61 
NUCLEUS 
202+46 
26+7 
(P<0.05) 
21+8 
(P<0.05) 
CYTOSOL 
162+9.9 
144+24 
326+42 
(P<0.05) 
PLASMA TESTOSTERONE 
(NG/ML) 
1. 77+0.23 
0.78+0.20 
(P<0.05) 
1. 53+0. 32 
As total hepatic androgen receptor activity and plasma 
testosterone values were reduced in the spironolactone-treated 
animals, the activity of a hepatic androgen responsive protein, a 
male specific estrogen binder (MEB), was also assessed (Tab II). 
Tab II: Activity of an androgen responsive protein in rat liver 
CONTROL 
SPIRO 
K-CANREO 
MEB (pmol/mg protein) 
2.41+1 
o 
6.3+1.5 (p<0.05) 
The activity of this protein is undetectable in the livers of 
the spironolactone treated animals; this loss of MEB activity is 
comparable to that seen in rats castrated at least 15 days prior 
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to sacrifice (14,36). However MEB level in k-carenoate treated 
rats is actually higher than that observed in the control tats. 
To determine whether either of these drugs might interfer by 
competing for androgen binding to its receptor, we tested whether 
they were capable of competing for androgen receptor binding in 
an in vitro assay. 
Spironolactone, at a 100 and 1000-fold excess, is partially 
effective as a competitor for 3H - R188l binding in rat liver 
cytosol. However, the strong androgen R188l and DHT are much more 
effective competitors than is spironolactone. In contrast, k-
canrenoate is incapable of competing for 3H - R1881 binding at 
any concentration tested. 
The activity of cytosolic estrogen receptors (cER) (Tab IIi) 
were virtually unchanged among the 3 groups, nor did the affinity 
of cER for E2 vary among the groups of animals (Kd values for cER 
were 0.26i9.07 nM, 0.45i9.l2 nM and 0.36!0.08 nM for group I, II 
and III respectively). The activity of nuclear estrogen receptor 
(nER) was decreased significantly only in the spironolactone 
treated animals. However, the total hepatic estrogen receptor 
content does not vary in the 3 groups of animals studied. This 
latter finding is consistent with the similar plasma estradiol 
values in these three groups of animals. 
Tab III: Variation in hepatic estrogen receptor activity in rat 
liver 
CONTROL 
SPIRO 
K-CAN 
3H -E2 specific binding (pmol/g liver) 
TOTAL 
623+115 
549+89 
650+222 
NUCLEUS 
178+33 
16+12 
(P<0.05) 
209+44 
CYTOSOL 
445+61 
533+150 
441+94 
DISCUSSION 
PLASMA ESTRADIOL 
(PG/ML) 
9.52+1.73 
7.82+3.04 
9.91+1.13 
Sexual dimorphism of liver function has been observed in both 
animals and humans (reviewed in 11). 
In male rats, androgen is the major steroid hormone deter-
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minant of the 
stimulates the 
masculine pattern of liver function. Androgen 
expression of both androgen receptor and certain 
enzymes and proteins such as the male specific estrogen binder 
MEB (14,36). This masculine pattern can be feminized by certain 
changes in serum hormone levels occuring after castration 
(14,36), chronic alcohol ingestion (13), estrogen treatment (21), 
portal vein ligation (15) and during liver regeneration (16,18). 
Our results present that administration of spironolactone, 
resulted in a significant decrease in plasma of testosterone 
levels and hepatic androgen receptors (AR), and the complete loss 
of activity of the hepatic androgen responsive protein (MEB), 
that is a cytosolic protein which has a moderate affinity for 
estradiol, high binding capacity, and specificity for steroid 
estrogen (12,34,36). Its function in the cytosol of male rats is 
unknown, but may be that of an intracellular estrogen scavenger 
(12,34). The complete disappearance of MEB in rats treated with 
spironolactone is significant, first, in that its loss represents 
interruption of hepatic androgen response, and second, that its 
absence might lead to an increased intracellular estrogen 
concentration. 
Plasma estradiol, estriol content, and the total ER activity 
in liver don't result to be influenced by spironolactone. It is 
possible that our treatment period was too short to produce a 
feminization of (i.e. an increase in) these activities. It is 
more likely, however, that in liver disease patients, feminiza-
tion occurs because spironolactone treatment interferes in main-
taining the androgenic influence necessary to sustain a masculine 
pattern of liver function. Such interference, coupled with an al-
ready compromised ability to excrete estrogens, may permit full 
feminization of liver and other peripheral tissues, such as the 
breast. 
Patients with liver disease may also fail to clear efficiently 
othe~ hormones such as prolactin which may enhance devolopment of 
gynecomastia. However, our experimental animals display no liver 
diseases; thus, treatment of normal male animals with spironolac-
tone may not result in the pronounced feminization that has been 
noted in some liver 
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testosterone, total hepatic androgen receptor or MEB, and no in-
hibition of androgen binding to its receptor were found to occur 
in the liver of the potassium canrenoate treated animals. 
In conclusion, the data reported in this paper demonstrate 
that spironolactone treatment of male rats decreased plasma 
testosterone, and exhibited a powerful anti-androgenic effect 
(low levels of hepatic androgen receptor and disappearance of 
MEB). We also demonstrated that potassium canrenoate did not show 
any of the anti-androgenic actions of spironolactone in the 
liver, suggesting that the clinical improvement reported in 
patients treated with potassium canrenoate as compared to 
spironolactone is the result of this biochemical difference. 
Also, our results indicate that in animals with no underlying 
liver disease, feminization, defined as an increase in plasma 
estrogen levels and hepatic ER content, does not occur. 
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